Study Aims
The Real World Clinical Outcomes with Novel Modulator Therapy Combinations in People with CF (RECOVER) – Is a real-world non interventional study examining the impact of the new triple combination CFTR modulator compound, Kaftrio®, on clinical outcomes in people with Cystic Fibrosis.
RECOVER aims to:
⦿ Determine the effect of Kaftrio® on pulmonary function (FEV1 and LCI) in children and adults with CF over a period of 2 years.
⦿ Determine the effect of Kaftrio® on spirometry-controlled CT scores in children and adults with CF over a 2-year period.
⦿ Investigate the effect of Kaftrio® on airway infection and inflammation in children and adults with CF.
⦿ Assess the effect of Kaftrio® on nutrition, gastrointestinal symptoms, gut inflammation and pancreatic functions in children and adults with CF over a 2-year period.
⦿ Determine the effect of Kaftrio® on antibiotic treatment of pulmonary disease in children and adults with CF over a 2-year period.
⦿ Assess the impact of the introduction of Kaftrio® on adherence with overall medical treatments for CF.
⦿ Assess adolescents’ experience since starting Kaftrio® and young children’s understanding of CF and the treatments they receive.